Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The immune modulatory molecule CTLA-4 (CD152), through interactions with the B7 costimulatory molecules, has been shown to be a negative regulator of T cell activation in various murine model systems. Abs that block CTLA-4 function can enhance immune responses that mediate potent antitumor activity. However, CTLA-4 blockade can also exacerbate autoimmune disease. The safety and activity of anti-CTLA-4 Abs in primates has not been addressed. To that end, we generated human Abs against CTLA-4 using transgenic mice expressing human Ig genes. A high affinity Ab (10D1) that blocked the binding of CTLA-4 to the B7-1 and B7-2 ligands and had cross-reactivity with macaque CTLA-4 was chosen for further development. Administration of 10D1 to cynomolgus macaques significantly enhanced Ab responses to hepatitis surface Ag and a human melanoma cell vaccine. Anti-self Ab responses as measured by immunoassays using lysate from melanocyte-rich tissues were elicited in those animals receiving the melanoma cell vaccine and anti-CTLA-4 Ab. Remarkably, chronic administration of 10D1 did not result in measurable polyclonal T cell activation, significant alteration of the lymphocyte subsets, or induce clinically observable autoimmunity. Repeated dosing of the 10D1 did not elicit monkey anti-human Ab responses in the monkeys. These observations support the development of CTLA-4 blockade for human immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · cited 1×
“This mechanism of T cell inactivation by CTLA-4 is important in regulation of peripheral T cell homeostasis, an activity that is most dramatically demonstrated in CTLA-4 knockout mice, which exhibit massive lymphoproliferation leading to death at 3–4 wk of age (14, 15).”
BackgroundLymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · cited 1×
“This mechanism of T cell inactivation by CTLA-4 is important in regulation of peripheral T cell homeostasis, an activity that is most dramatically demonstrated in CTLA-4 knockout mice, which exhibit massive lymphoproliferation leading to death at 3–4 wk of age (14, 15).”
BackgroundCD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“The mechanism by which antitumor responses are augmented as a result of treatment with anti-CTLA-4 mAbs is thought to be dependent on the inhibition of CTLA-4 engagement of the B7 costimulatory molecules expressed on APCs (1, 11).”
BackgroundTakahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · cited 1×
“In a preliminary report of 14 patients receiving anti-CTLA-4 together with melanoma peptides, several tumor responses (two complete responses and one partial response) have been observed (41).”
BackgroundSelf-citationvan Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · cited 2×
“However, with less responsive tumors a combination of anti-CTLA-4 Ab with additional treatments such as active immunization with tumor Ag vaccines (7, 8), surgery (9), or chemotherapy (10) constitutes effective therapy.”
BackgroundSutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008 · cited 1×
“(37) have demonstrated that removal of this subset is synergistic with CTLA-4 blockade in a murine model of tumor immunotherapy, suggesting that anti-CTLA-4 treatment does not impact the T reg population.”
BackgroundHodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006 · cited 1×
“From immunohistochemical analysis of post-treatment tumor biopsies from these patients, it appears that CTLA-4 blockade enhanced tumor-directed immune responses in patients that received cellular vaccines (40).”
BackgroundSelf-citationCTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940 · cited 3×
“The mechanism by which antitumor responses are augmented as a result of treatment with anti-CTLA-4 mAbs is thought to be dependent on the inhibition of CTLA-4 engagement of the B7 costimulatory molecules expressed on APCs (1, 11).”
BackgroundMethod
Cited by
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857
“58a-b-CTLA-4/CD3z is a murine T-cell hybridoma that expresses murine CTLA-4 fused to CD3z and is analogous to a similar construct for humanCTLA-4 (17).”
BackgroundSelf-citationBeck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833
“A number of grade 3/4 immune-mediated toxicities, unanticipated by preclinical testing in nonhuman primates, were encountered in patients given ipilimumab.(11-13) These included dermatitis, enterocolitis, hypophysitis, uveitis, and hepatitis.”
BackgroundQuezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Metadata
- Authors
- Keler, T., Halk, E., Vitale, L., O’Neill, T., Blanset, D., Lee, S., Srinivasan, M., Graziano, R. F., Davis, T., Lonberg, N., & Korman, A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-12-01
- Volume
- 171
- Issue
- 11
- Pages
- 6251-6259
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2166980833
- Cited by
- 134
- References
- 10
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.